Business Context and Reporting Period
This Form 8-K is filed by Helius Medical Technologies, Inc. (not Solana Co) on July 7, 2025. The report addresses the company's regulatory status regarding its listing on The Nasdaq Capital Market under the trading symbol HSDT.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only financial metric referenced is the regulatory threshold for stockholders' equity, which must be at least $2.5 million to comply with Nasdaq Listing Rule 5550(b)(1).
Material Changes
- Regained Compliance: The Company received formal notification from Nasdaq on July 7, 2025, confirming it has regained compliance with the Equity Requirement.
- Previous Status: The Company had previously been granted a compliance period following a hearing on March 18, 2025, with a deadline of June 30, 2025.
- Minimum Bid Price: The Company had already regained compliance with the Minimum Bid Price Requirement as of June 3, 2025.
Outlook, Risks, and Contingencies
- Mandatory Monitoring: The Company is subject to a Mandatory Panel Monitor until July 7, 2026.
- Delisting Risk: If the Company falls out of compliance with the Equity Requirement again within the one-year monitoring period, it will not be permitted to submit a plan of compliance or receive additional cure time. Instead, Nasdaq staff would issue a "Delist Determination Letter," leading to a potential hearing for delisting.
Investor Verification Checklist
- Verify the current stock price and market capitalization to ensure continued compliance with the $2.5 million equity threshold.
- Confirm the company's status regarding the Mandatory Panel Monitor period ending July 7, 2026.
- Review subsequent filings for any updates on stockholder equity levels or potential delisting notices.
- Note the discrepancy between the requested company name (Solana Co) and the actual registrant (Helius Medical Technologies, Inc.).